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Abstract
Background: Neonatal lactic acidosis can be associated to severe inborn errors of metabolism. Rapid identification
of the underlying disorder may improve the clinical management through reliable counseling of the parents and
adaptation of the treatment.
Methods: We present the case of a term newborn with persistent hypoglycemia on postnatal day 1, who
developed severe lactic acidosis, aggravating under intravenous glucose administration. Routine metabolic
investigations revealed elevated pyruvate and lactate levels in urine, and magnetic resonance spectroscopy
showed a lactic acid peak and decreased N-acetylaspartate levels. Mitochondrial disorders, e.g., pyruvate
dehydrogenase (PDH) deficiency, were the major differential diagnoses. However, both hypoglycemia and the
elevated lactate to pyruvate ratio in serum (=55.2) were not typical for PDH deficiency. We used “Mendeliome
sequencing”, a next-generation sequencing approach targeting all genes which have been previously linked to
single-gene disorders, to obtain the correct diagnosis.
Results: On day 27 of life, we identified a homozygous stop mutation in the PDHX gene, causing pyruvate
dehydrogenase E3-binding protein deficiency. After starting the ketogenic diet, the infant recovered and is
showing delayed but progressive development.
Conclusions: Mendeliome sequencing was successfully used to disentangle the underlying cause of severe
neonatal lactic acidosis. Indeed, it is one of several targeted sequencing approaches that allow rapid and
reliable counseling of the parents, adaptation of the clinical management, and renunciation of unnecessary,
potentially invasive and often costly diagnostic measures.
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Background
Neonatal lactic acidosis can be associated to a heteroge-
neous spectrum of causes, ranging from benign (e.g.,
protracted postnatal adaptation) to severe, potentially
life-threatening conditions, e.g., disorders of energy me-
tabolism such as deficiency of the pyruvate dehydrogenase
(PDH) complex. PDH deficiency is the most common bio-
chemically proven cause of congenital lactic acidosis [1]
and thus an important differential diagnosis, particularly
as treatment approaches exist. The PDH complex is a large
(approx. 8 MDa) nuclear-encoded multi-enzyme complex
located in the mitochondrial matrix and formed by three
functional subunits (E1, E2, and E3 plus the E3-binding
protein (E3BP)). It catalyzes the oxidation of pyruvate to
acetyl coenzyme A and thereby links cytoplasmic gly-
colysis to the intra-mitochondrial tricarboxylic acid
cycle. Deficiency of the PDH complex leads to accumu-
lation of pyruvate and lactic acid as well as impaired
mitochondrial energy restoration which is particularly
harmful to the brain leading to impaired life expectancy
and neurocognitive development. PDH deficiency can
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be caused by mutations in several different genes (e.g.,
PDHA1 [OMIM 300502], PDHX [608769], PDHB [179060],
DLAT [608770]; see [2] for overview). Additionally, an
increasing number of mutations have been found in genes
that encode for co-factors of pyruvate oxidation (e.g.,
thiamine), resembling the wide clinical spectrum of PDH
deficiency [2] that embraces phenotypes which are primarily
metabolic (i.e., severe neonatal lactic acidosis) and those
which are rather neurologic (i.e., muscular hypotonia and
congenital brain malformations, e.g., agenesis of corpus cal-
losum). The E3BP of the PDH complex is encoded by the
pyruvate dehydrogenase complex-component X (PDHX)
gene. After PDHA1, PDHX is the second most commonly
mutated gene in PDH deficiency [3]. So far, a genotype-
phenotype correlation has not been established due to the
different affected domains of E3BP and the heterogeneity
of the clinical features [4].
In contrast to other possible causes of neonatal lactic
acidosis, there is currently no fully satisfying treatment
available for patients with PDH deficiency [5]. However,
ketogenic diet (KD) has been shown to positively influ-
ence the outcome of patients with PDH deficiency as it
provides an alternative energy source and thereby by-
passes the detrimental energy deprivation [2, 6]. In case
PDH deficiency underlies neonatal lactic acidosis, early
initiation of KD supposedly correlates with improved
long-term outcome [7]. Precise diagnosis before the start
of KD is required as there are contra-indications in some
cases of lactic acidosis; KD should be avoided in some
defects of the mitochondrial respiratory chain [8, 9] and
in pyruvate carboxylase deficiency [8, 10] as it can en-
hance lactic acidosis and deteriorate the clinical situation
[9, 10]. Currently, the diagnostic approach to monogen-
etic disorders such as PDH deficiency is experiencing
pivotal changes. While previously, newborns and infants
often underwent invasive, time-consuming, and costly
diagnostic procedures—yet in some cases with ambigu-
ous and inconclusive results [11]—next-generation se-
quencing approaches are increasingly implemented in
daily clinical practice. Here, we illustrate in a case of
neonatal lactic acidosis that a disease gene panel based
on a targeted next-generation sequencing (NGS) meth-
od—an approach that we term “Mendeliome sequen-
cing”—can be successfully applied. This NGS approach
allows targeted sequencing of all disease genes listed in
the Online Mendelian Inheritance of Man (OMIM)
database.
Methods
The study was approved by the institutional review
board of the Ethics Committee of the University Hos-
pital of Cologne. Informed consent for research and
publication was obtained from the family.
Case description
We present the case of a male newborn of Turkish-origin
parents who was born at term at a peripheral children’s
hospital. The parents stated to be non-consanguineous
but belonged both to an endogamic subpopulation from
Turkey. The patient’s younger sister was healthy while the
older sister suffered from agenesis of corpus callosum and
severe psychomotor retardation; as the parents have been
rejecting any genetic counseling, the etiology of her dis-
ease remains unknown. After a complicated pregnancy
(maternal diabetes mellitus, placenta previa, HELLP syn-
drome), the boy was born by secondary caesarian section
due to placental abruption. Initial postnatal adaptation
was unremarkable, but routine check of blood sugar levels
(in response to maternal diabetes mellitus) first revealed
repetitive neonatal hypoglycemia (8 h of age) and later on
spontaneous development of moderate lactic acidosis
(13 h of age: lactic acid 8.6 mmol/l (normal, ≤ 2.1 mmol/
l); pH 7336). As hypoglycemia did not improve under re-
petitive feeding, intravenous (i.v.) glucose administration
(6 mg/kg body weight/min.) was necessary (starting at
14 h of age). However, after a bolus application of glucose
(10 %, 2 ml/kg body weight), the patient developed hyper-
glycemia (max. 397 mg/dl) and further worsening of lactic
acidosis (24 h of age: lactic acid 16 mmol/l; pH 7037)
which barely improved despite subsequent reduction of
glucose supply and buffering with bicarbonate. Thus, an
inborn error of metabolism was suspected, and the boy
was transferred to the University Children’s Hospital 25 h
after birth. Though he remained clinically unimpaired,
lactic acidosis worsened (27 h of age: pH 7.0, lactic acid
18 mmol/l, base excess −21). Further investigations
showed ketone bodies in urine as well as mildly elevated
liver enzyme and CRP levels, in response to which antibi-
otics were started (and again terminated 5 days later after
exclusion of neonatal infection; cultures of blood and
cerebrospinal fluid were unremarkable). Despite extensive
metabolic screening, the diagnosis remained elusive (nor-
mal values for newborn screening, ammonium, serum
acylcarnitines/carnitine, urine amino acids, urine organic
acids, very long chain fatty acids (VLCFA), homocystein,
purines/pyrimidines in urine; plasma amino acids: ele-
vated alanine secondary to lactic acidosis [1054 μmol/l,
normal <710 μmol/l]). A mitochondrial disorder was now
suggested as the underlying cause for several reasons:
aggravation of lactic acidosis under i.v. glucose supply;
increased levels of pyruvate and lactic acid in urine (both
>5000 mmol/mol creatinine, normal: lactic acid <285,
pyruvate <130); and finally, the findings of a magnetic res-
onance (MR) spectroscopy performed on day 6 after birth,
that showed lactic acid peaks in the right occipital and
frontal cortical areas under involvement of the subcortical
white matter. Alterations of brain morphology, in particu-
lar agenesis of corpus callosum as seen in his older sister
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and as previously described for PDH deficiency, were
not present. Buffering via bicarbonate administration
was stopped on postnatal day 3, and tentative treatment
with thiamine (75 mg/kg body weight/day) and carni-
tine (100 mg/kg body weight/day) was started. How-
ever, two findings—the initially observed refractory
hypoglycemia and the elevated lactate to pyruvate ratio
in the blood (55.2 = 6.9 mmol/l [lactate] to 0.125 mmol/l
[pyruvate] in blood samples taken simultaneously)—were
not characteristic of PDH deficiency and could have been
each of them caused by many other inborn errors of me-
tabolism [2, 4]. On postnatal day 16, we therefore applied
a genetic approach to identify the underlying disorder.
Sample preparation and sequencing analysis
DNA was extracted from blood with standard protocols.
We performed next-generation sequencing for Mendelian
diseases—which we term Mendeliome sequencing—in
order to clarify the diagnosis. Fifty nanogram of genomic
DNA (gDNA) were used for the TruSight One Sequencing
Panel (Illumina) library prep protocol (Number 15046433,
2013). After quality control and quantification, the library
was pooled and enriched for 4813 genes associated to
monogenetic disorders. The pool underwent qPCR as a
final control step and was loaded on an Illumina MiSeq
benchtop sequencer using v3 chemistry and a 2 × 150 bp
read length. The Cologne Center for Genomics VAR-
BANK pipeline v.2.12 (https://varbank.ccg.uni-koeln.de/)
was used for data analysis (Table 1).
Results
Genetic work-up
By sequencing, a mean coverage of 82 % was reached, 10×
coverage was 97.5 % for target sequences and 30× coverage
was 87.1 % on target (Additional file 1: Table S1). After ana-
lysis by our in-house software VARBANK v.2.12 (https://
varbank.ccg.uni-koeln.de/), we deciphered the underlying
condition within 11 days, i.e., at postnatal day 27. Initially,
we looked for homozygous variants located in the shared
runs of homozygosity (ROH). For completion, we also per-
formed a further analysis of other possible heterozygous
variants which did not reveal any mutation that could ex-
plain the biochemical and clinical features in this newborn.
After filters were applied, the number of variants was re-
duced to five. Further filtering was performed on the basis
of quality of reads, frequency in the population, prediction
of pathogenicity, and evolutionary conservation, leading to
one disease-causing genetic variant (Table 2).
We diagnosed pyruvate dehydrogenase E3-binding pro-
tein deficiency (OMIM 245349) by detecting a homozygous
stop mutation in the PDHX gene (c.1336C>T in exon 11
causing p.R446* according to NM_003477.2) (Fig. 1). The
PDHX variant was tested by Sanger sequencing, and the
mutation was shown to be co-segregating within the family.
The p.R446* allele was not present in the Exome Aggrega-
tion Consortium (http://exac.broadinstitute.org/) and the
Exome Variant Server (http://evs.gs.washington.edu/EVS/).
We show the excellent coverage of the Mendeliome se-
quencing for the PDHX gene in Additional file 2: Figure S1.
Discussion
We present a newborn with severe neonatal lactic acidosis
in which we applied a NGS technique to identify pyruvate
dehydrogenase E3-binding protein deficiency as the under-
lying disorder. Once the genetic diagnosis was made, KD
(3:1) was started (on postnatal day 28) and lactic acid
values were thereby normalized. Despite sufficient caloric
intake (~180 kcal/kg body weight/day), the patient devel-
oped failure to thrive at the beginning of KD. Showing
signs of exocrine pancreatic insufficiency (pancreatic
elastase in stool, 72 μg/g stool; normal, >200), the boy re-
ceived pancreatin as exogenous replacement therapy (for
Table 1 Pipeline and filter parameters used for Mendeliome
sequencing (filter metrics)
Filter parameter Patient
Reads variation allele frequency range 75–100 %
Maximal number of allowed variations
per gene
10
Maximal number seen in epilepsy
in-house DM (n = 511)
5
Maximal number seen in structural
in-house DM (n = 611)
10
Maximal population variation frequency 0.1 %
Minimal read coverage 6
Minimal variation quality 10
Maximal target distance 100
Transcryptic biotypes protein_coding
Variation locations COMPOSED (variation spans
different parts of a gene),
intron, CDS (coding sequence)
Consequence types Protein structure affected;
cryptic 5′SS/3′SS activation;
strong 5′SS/3′SS effects
Table 2 Sequentially listed filtering steps for homozygous
analysis
ROH
Rare functional variants (RFV) 5
Non-synonymous coding, indels 4
RFVs in good sequence quality (Q > 100) 4
RFVs not reported in dbSNP database 2
Non-reported RFVs predicted to be disease causing 1
ROH regions of homozygosity
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approximately 2 months). He profited of this treatment
and showed adequate weight gain, even after termination
of pancreatin treatment. In contrast to other rare forms of
mitochondrial disorders, particularly Pearson syndrome
[12], exocrine pancreas insufficiency has not been de-
scribed in PDH deficiency. As discussed in a previous case
report, this might represent a particular complication of
KD treatment in very young infants [13]. At 7 months of
age, our patient had developed a secondary microcephaly
and had a moderate delay of motor development. Other
comorbidities have not (yet) occurred.
The mutation (p.Arg446*) was recently described as a
founder mutation in 60 % of the patients of the Roma
population who presented with congenital lactic acidosis
[14]. Later in life, these patients mostly suffer from spastic
diplegia, epileptic seizures, cortical brain atrophy, ven-
tricular enlargement, and mental retardation [14]. Though
a genotype-phenotype correlation has not been well estab-
lished for PDH deficiency, these findings suggest that this
particular mutation could be associated to a severe out-
come, underlining the need to counteract long-term de-
velopmental impairment as much as possible. Numerous
case reports [7, 15] and a study in zebrafish [16] have
shown the potential therapeutic benefit of KD in PDH
deficiency. It has been suggested that early initiation
of KD in PDH deficiency might improve patients’
long-term outcome [7]. This would also have socio-
economic implications.
However, rapid diagnosis of PDH deficiency is challen-
ging as it is often not possible to separate it from other
mitochondrial disorders by mere clinical observation and
specific metabolites/biochemical findings [2]. Indeed, we
were misled by the lactate/pyruvate ratio in the blood
(=55.2) that was unusually high for PDH deficiency [2, 4]
but could have fitted to defects of the mitochondrial re-
spiratory chain complex I or IV [17]. This indicates that
caution needs to be warranted in the interpretation of the
L/P ratio, especially if the ratio was only measured once,
as in our case. Previously, the diagnosis of PDH deficiency
was primarily based on laborious biochemical enzymatic
assays of, e.g., muscle tissue or cultured fibroblasts usually
being both time-consuming and potentially inconclusive,
in particular in very young infants under 3 months of age.
Furthermore, depending on the X-inactivation pattern,
cases of X-chromosomal PDHA1 deficiency can be missed
with biochemical assays [2]. Thus, there is a need for fast
Fig. 1 Mendeliome reads show PDHX mutation. Reads from the patient’s genome show homozygous change from C to T (https://varbank.ccg.uni-
koeln.de/). Above in black capital letters are the genomic reference sequence and the hg19 coordinates. Below is the next-generation sequencing read
alignment, small and capital letters correspond to different sequencing directions. The mutation is labeled in red
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and reliable methods to identify patients with PDH defi-
ciency. Targeted next-generation sequencing panels have
been shown to ease this need. Targeted gene sequencing
panels may cover all (coding) exons of the human gen-
ome, i.e., whole-exome sequencing (WES), or a selection
of exons in a limited number of relevant genes. Whole-
genome sequencing (WGS) aims to cover the entire hu-
man genome including the non-coding regions. Recently,
it has been shown that in child neurology practice, a sub-
stantial part of the patients profited from WGS because
it led to the genetic identification of the underlying dis-
order [18]. The resulting implications are more than
just therapeutic ones: the general clinical management
of the patient and its family—e.g., by facilitating par-
ents’ decision-making in end-of-life situations—may be
substantially improved by fast genetic diagnoses. Targeted
next-generation sequencing panels—such as for metabolic
disorders, mitochondrial disorders or as in our case the
Mendeliome—have several advantages. Compared to WGS
or WES, a restriction to candidate genes—selected based
on the clinical presentation of the patient and/or restricted
to all known OMIM-listed genes—is cheaper and quicker
and detects clinically relevant variant interpretation of
known disease genes easier. From a broad perspective, se-
quencing off all OMIM-listed genes by the Mendeliome
additionally offers the advantage to detect unusual links of
clinical presentations and genetic mutations (genotype-
phenotype correlations). Current studies of rapid WGS in
neonatal settings show a high detection rate of deep in-
tronic variants, which carries the problem of higher false
positive rates and expensive, compelling, labor-intensive
variant testing [19]. Targeted NGS panels (e.g., restricted on
inborn errors of metabolism or the Mendeliome) have
shorter turn-around times compared to standard WGS and
WES. Rapid WGS however is comparably quick, providing
the molecular diagnosis within 26 to 50 h [20–22]. How-
ever, this WGS approach needs expensive hardware and
computational clusters that are only available in large
genome centers of developed countries. Mendeliome se-
quencing has restrictions, of course. It has not been de-
signed to detect deep intronic mutations, which currently
can only be detected by WGS. Also, Mendeliome sequen-
cing requires regular updates of the targeted genes. Further,
low coverage in certain exons of a number of genes might
lead to false negative results, requiring further technical
optimization. However, our recent unpublished data shows
that certain genomic regions are even elusive to WGS and
can only be sequenced by special techniques (data not
shown). Structural variants including copy number variants
are difficult to detect with targeted gene panels using NGS.
Although several algorithms based on coverage statistics
have been developed, false positive and negative rates are
very high in particular for heterozygous copy number vari-
ants. Further bioinformatic analysis with computational
tools under development might make the identification of
large structural variants and copy number variations more
reliable in the future. In contrast, Mendeliome sequencing
and other targeted NGS panels could be established in any
molecular genetic laboratory and can be run by benchtop
NGS machines while the data analysis can be performed on
up-to-date standard computers.
The presented case shows that Mendeliome sequencing
can be applied in case of neonatal lactic acidosis, providing
the diagnosis and thereby enabling initiation of treatment.
It took us 11 days from initiation of genetic investigation
(on postnatal day 16) until finding of the diagnosis (on
postnatal day 27). That was due to the fact that Mende-
liome sequencing is not yet established in the daily clinical
routine and that it is not a first-line diagnostic method.
Thus, it was conducted in our research laboratory which
obviously takes much longer. However, if this novel
method is established in the clinical routine, Mendeliome
sequencing is feasible within 72 h (Illumina Truesight One
Manual 15046433, 2013). For cases of PDH deficiency in
particular, Mendeliome sequencing is quicker than the
previously used enzymatic assays. Our case of pyruvate de-
hydrogenase E3-binding protein deficiency could have
equally been solved by targeted gene panels restricted on
inborn errors of metabolism and/or mitochondrial disor-
ders. The decision whether to choose smaller gene panels
or the Mendeliome panel should be based on careful clin-
ical judgment, which might also depend on the availability
of subspecialty experts. Mendeliome sequencing is a novel
diagnostic tool that might in the future become a valuable
supplement to classical biochemical approaches. It is con-
ceivable that Mendeliome could be preferentially applied
in clinical settings with largely unspecific and undefined
phenotypes and/or misleading biochemical findings (which
we personally experienced in this particular case). The
more specific a phenotype is (and the less ambiguous
potential biochemical findings are), the more likely more
restrictive targeted gene panels (e.g., for mitochondrial dis-
orders) could potentially be used.
Conclusions
In summary, this case shows the feasibility of Mendeliome
sequencing as a method that can be useful in patients with
neonatal lactic acidosis to rapidly identify cases of pyru-
vate dehydrogenase deficiency. Thus, together with nu-
merous previous NGS publications, our case indicates
that rapid genetic diagnosis via targeted sequencing
panels (e.g., Mendeliome sequencing) may improve the
long-term outcome of patients with treatable metabolic
or other inherited disorders. The utility of next-generation
sequencing panels in comparison to conventional meta-
bolic testing needs to be validated in the clinical routine
settings.
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Additional file 1: Table S1. Total number of reads and coverage
analysis of Mendeliome data.
Additional file 2: Figure S1. Coverage analysis of the PDHX gene.
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